By THE ASSOCIATED PRESSMARCH 28, 2016
Shares of Valeant dropped more than 7 percent on Monday after the Senate committee on aging said in a statement that Valeant’s chief executive, J. Michael Pearson, was among the witnesses expected to testify on April 27 at a hearing on fast-rising drug prices.Executives from Valeant, Turing Pharmaceuticals and other drug companies have been invited or subpoenaed to testify at hearings on the issue held by multiple congressional committees. The hearing in April is the third by the Senate committee since December.Drug makers have been buying up rights to old drugs and then raising prices many times over what they had been. The resulting prices — $100,000 or more for a course of treatment — are straining the budgets of patients, insurers and government health programs.A version of this article appears in print on March 29, 2016, on Page B3 of the New York edition with the headline: Valeant’s Chief Asked to Testify.  Order Reprints| Today's Paper|Subscribe

We’re interested in your feedback on this page. Tell us what you think.